Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 10/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BMP1 | P13497 | 1/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19996650 | 1.00 | FURIN (0.37) | FURINSIRT6SIRT1SMN1; SMN2BMP1 | |
| SCHEMBL22351933 | 1.00 | FURIN (0.37) | FURINSIRT6SIRT1SMN1; SMN2BMP1 | |
| SCHEMBL21897483 | 0.90 | FURIN (0.39) | FURINSIRT6SIRT1BMP1C3AR1 | |
| SCHEMBL20795891 | 0.89 | FURIN (0.36) | FURINSIRT6SIRT1SMN1; SMN2BMP1 | |
| SCHEMBL20159819 | 0.89 | FURIN (0.36) | FURINSIRT6SIRT1SMN1; SMN2BMP1 | |
| SCHEMBL23736705 | 0.89 | FURIN (0.36) | FURINSIRT6SIRT1SMN1; SMN2BMP1 | |
| SCHEMBL24461995 | 0.88 | FURIN (0.37) | FURINSIRT6SIRT1SMN1; SMN2C3AR1 | |
| SCHEMBL24015397 | 0.88 | FURIN (0.36) | FURINSIRT6SIRT1SMN1; SMN2C3AR1 | |
| SCHEMBL18818127 | 0.88 | SIRT6 (0.36) | FURINSIRT6SIRT1SMN1; SMN2C3AR1 | |
| SCHEMBL19101872 | 0.88 | FURIN (0.36) | FURINSIRT6SIRT1SMN1; SMN2C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9480754-B2 | Phospholipid ether analogs as cancer-targeting drug vehicles | CELLECTAR BIOSCIENCES, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160228564-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | CELLECTAR BIOSCIENCES INC (US) | 2016-08-11 | — | — | US | disclosed |
| US-9345718-B1 | Phospholipid ether analogs as cancer-targeting drug vehicles | CELLECTAR BIOSCIENCES, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160136190-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | CELLECTAR BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160136290-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | CELLECTAR BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136190-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | PHOSPHO1, MCL1, LPCAT3 | FURIN 2586/4885SIRT6 2486/4885SIRT1 2554/4885 |
| US-20160228564-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | PHOSPHO1, MCL1, LPCAT3 | FURIN 2586/4885SIRT6 2486/4885SIRT1 2554/4885 |
| US-20160136290-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | PHOSPHO1, MCL1, LPCAT3 | FURIN 2586/4885SIRT6 2486/4885SIRT1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.